Cargando…
Factors Associated with Recurrent Heart Failure during Incorporating SGLT2 Inhibitors in Patients Hospitalized for Acute Decompensated Heart Failure
Background: Sodium-glucose cotransporter 2 inhibitors (SGLT2i) reduce the risk of hospitalization for heart failure (HF) or death from cardiovascular causes among patients with chronic HF. However, little is known about the specific factors associated with clinical events during SGLT2i therapy in pa...
Autores principales: | Nakagaito, Masaki, Imamura, Teruhiko, Joho, Shuji, Ushijima, Ryuichi, Nakamura, Makiko, Kinugawa, Koichiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9457103/ https://www.ncbi.nlm.nih.gov/pubmed/36078956 http://dx.doi.org/10.3390/jcm11175027 |
Ejemplares similares
-
Renoprotective effects of sodium glucose cotransporter 2 inhibitors in type 2 diabetes patients with decompensated heart failure
por: Nakagaito, Masaki, et al.
Publicado: (2021) -
Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus
por: Nakagaito, Masaki, et al.
Publicado: (2019) -
Predictors and Outcomes of SGLT2 Inhibitor Discontinuation in a Real-World Population after Hospitalization for Heart Failure
por: Nakagaito, Masaki, et al.
Publicado: (2023) -
Initial Real-World Practical Experience of Sacubitril/Valsartan Treatment in Japanese Patients With Chronic Heart Failure
por: Nakamura, Makiko, et al.
Publicado: (2021) -
Urinary Isoxanthopterin in Heart Failure Patients
por: Hori, Masakazu, et al.
Publicado: (2021)